KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Assets (2016 - 2026)

Biocryst Pharmaceuticals filings provide 16 years of Assets readings, the most recent being $514.2 million for Q4 2025.

  • On a quarterly basis, Assets rose 4.84% to $514.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $514.2 million, a 4.84% increase, with the full-year FY2025 number at $514.2 million, up 4.84% from a year prior.
  • Assets hit $514.2 million in Q4 2025 for Biocryst Pharmaceuticals, up from $446.4 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $588.2 million in Q4 2021 to a low of $265.8 million in Q3 2021.
  • Median Assets over the past 5 years was $500.5 million (2023), compared with a mean of $473.1 million.
  • Biggest five-year swings in Assets: surged 110.19% in 2022 and later fell 10.84% in 2024.
  • Biocryst Pharmaceuticals' Assets stood at $588.2 million in 2021, then decreased by 6.49% to $550.0 million in 2022, then dropped by 6.01% to $517.0 million in 2023, then decreased by 5.13% to $490.4 million in 2024, then increased by 4.84% to $514.2 million in 2025.
  • The last three reported values for Assets were $514.2 million (Q4 2025), $446.4 million (Q3 2025), and $457.2 million (Q2 2025) per Business Quant data.